Forbes December 15, 2023
John LaMattina

For over 100 years, the U.S. has believed that investments in basic research were important for the public good – for our defense, for our health and for our economic prosperity. Furthermore, for these investments to be of value, any progress has to be broadly disseminated and made available so that it can contribute to the common good. Back in 1980, Congress was concerned about U.S. industry competitiveness believing that intellectual property being generated by government funds was not being utilized. This led to the passage of the Bayh-Dole Act which enabled small companies and universities to retain title to inventions made under federally funded research programs. This was instrumental in encouraging universities to participate in technology transfer activities thereby...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, HHS, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article